Oragenics Inc

OGEN

1.130USD

-0.090-7.38%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

Oragenics Inc's Score

Industry at a Glance

Industry Ranking

161 / 407

Overall Ranking

286 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

2.000

Target Price

+63.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Oragenics Inc Highlights

StrengthsRisks

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

Overvalued

The company’s latest PE is -0.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 104.80K shares, increasing 44.18% quarter-over-quarter.

The company's current financial score is 6.79, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.79

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.27, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.06, which is -35.01% below the recent high of -0.04 and -8155.11% above the recent low of -4.93.

Score

Industry at a Glance

Previous score

6.27

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 161/407

No Data

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Oragenics Inc is 2.00, with a high of 2.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 5.54, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 1.35 and the support level at 1.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.42

Change

0.12

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Five Narrow Lane LP

82.21K

--

Clear Street LLC

70.62K

--

BofA Global Research (US)

15.55K

+221985.71%

Cassidy (Bruce A Sr)

11.82K

+0.03%

Morgan Stanley & Co. LLC

11.77K

+78380.00%

FNY Investment Advisers LLC

2.50K

--

UBS Financial Services, Inc.

1.89K

+846.00%

Telling (Frederick W)

1.16K

--

Koski (Robert C)

931.00

--

Dunton (Alan W)

854.00

--



1

2



The company’s current risk assessment score is 2.74, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Oragenics Inc

OGEN

5.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment